PROMISING PROGRESS! 💥 The @fda has approved a new treatment for adults with multiple myeloma that has returned or continued to progress despite four earlier treatments. "This new treatment can help improve the outcome for many patients with hard-to-treat myeloma and is another incredible milestone in the immunotherapy approach to treating cancer," said Lee Greenberger, Ph.D., LLS Chief Scientific Officer. "LLS has been leading the way in immunotherapy, with research investments stretching back more than 20 years and more than $250M invested in this approach." Get the details through the 🔗 in our bio.